MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/bmjresp-2026-004532

Медицинская библиотека · BMJ open respiratory research · 2026

Effects of PERMISSive lung-protective ventilation on outcome in critically ill, invasively ventilated patients (PERMISS): protocol for a feasibility and safety randomised clinical trial.

Caroli Alessandro, Hoogenboom Amarens, Bugedo Guillermo, Damiani Felipe L, Ferreira Juliana, Abreu Marcelo Gama de, Geerts Jan-Willem, Grady Bart P, List Stephanie S, van Meenen David M P, Morales-Quinteros Luis, Paulus Frederique, Serpa Neto Ary, Schultz Marcus J, Slutsky Arthur S, Sodhi Kanwalpreet, Urlings-Strop Louise, Buiteman-Kruizinga Laura A, PERMISS collaborative group, PROVE network

Протокол клинического исследованияСтатьяПеревод в очереди

Аннотация

INTRODUCTION

Mechanical power (MP) of ventilation is a summary variable of determinants of ventilator-induced lung injury and is consistently associated with worse outcomes. Lung-protective ventilation (LPV) using a lower respiratory rate (RR) is an appealing strategy to reduce MP, but it is unclear whether reducing RR is feasible and safe in critically ill patients under invasive mechanical ventilation. Therefore, we test the hypothesis that a ventilation strategy that targets the lowest acceptable RR is feasible and safe.

METHODS AND ANALYSIS: The 'Effects of PERMISSive Lung-protective Ventilation on Outcome in Critically Ill, Invasively Ventilated Patients (PERMISS)' pilot study is an international, multicentre randomised clinical feasibility and safety trial in critically ill, invasively ventilated adult patients with an expected duration of ventilation >24 hours. Patients will be randomly assigned to 'permissive' LPV with a lower RR, within safety limits of arterial partial pressure of carbon dioxide (PaCO2) and pH, compared with conventional LPV with RR to target normal PaCO2 and pH. The primary endpoint is the difference in RR between the two groups from the start of ventilation until the first extubation. Secondary endpoints include safety, assessed by the incidence of unacceptable hypercapnia (PaCO2>70 mm Hg and pH<7.20), severe hypoxaemia (arterial partial pressure of oxygen (PaO2)<60 mm Hg), ventilator-associated complications and compliance with the protocol and quality of data collection.

ETHICS AND DISSEMINATION: The current version of the protocol is V.3 (issued on 11 December 2025). The trial was approved by the medical research ethics committee of Leiden Den Haag Delft (approval number NL-009624.P25.028) on 2 June 2025, including all amendments, and was registered on www.

CLINICALTRIALS: gov (NCT07077174). The PERMISS pilot is currently recruiting patients.

TRIAL REGISTRATION NUMBER: NCT07077174.

Для цитирования: Caroli Alessandro, Hoogenboom Amarens, Bugedo Guillermo, Damiani Felipe L, Ferreira Juliana, Abreu Marcelo Gama de, Geerts Jan-Willem, Grady Bart P, List Stephanie S, van Meenen David M P, Morales-Quinteros Luis, Paulus Frederique, Serpa Neto Ary, Schultz Marcus J, Slutsky Arthur S, Sodhi Kanwalpreet, Urlings-Strop Louise, Buiteman-Kruizinga Laura A, PERMISS collaborative group, PROVE network. Effects of PERMISSive lung-protective ventilation on outcome in critically ill, invasively ventilated patients (PERMISS): protocol for a feasibility and safety randomised clinical trial.. BMJ open respiratory research. 2026. DOI: 10.1136/bmjresp-2026-004532.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.